Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2020

US NHANES data highlight high prevalence of elevated triglycerides despite statin therapy

About one in four statin-treated adults have triglycerides ≥150 mg/dl (≥1.7 mmol/L), according to the latest data from the US National Health and Nutrition Examination Survey (NHANES, 2007–2014). Elevated triglycerides are recognized as a risk factor for atherosclerotic cardiovascular disease. While guidelines recommend statins as a first treatment option, this may be insufficient in a substantial proportion of patients. These new survey data aimed to evaluate the prevalence of elevated triglycerides ≥150 mg/dL (recommended as the upper limit for desirable triglyceride levels) among US statin-treated patients, using data from NHANES. Overall, the results showed that 25.9% of statin-treated patients have triglycerides ≥150 mg/dL; this translates to 12.3 million people in the USA. These findings underline the need for new approaches to address this unmet clinical need and reduce the residual cardiovascular risk associated with elevated triglycerides in these patients.
Prevalence of US Adults with Triglycerides ≥150mg/dl: NHANES 2007–2014.

Fan W, Philip S, Granowitz C et al.